// App-Quantinova.ai

828P : Durable prostate cancer control in a randomized trial of optimal timing of dose escalated (76 Gy) radiation and 6 months ADT in prostate cancer

Researchers

Presenter

  • S.Malone

Principal Investigators

  • L.Eapen

  • W.Kendal

  • J.Craig

  • R.Macrae

  • G.Perry

  • J.Bowen

  • S.Morgan

  • O.Holmes

  • S.Grimes

Medical Centers

  • Radiation Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

  • Clinical Trials, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada

  • Radiation Oncology, N E Ontario Regional Cancer Centre, Sudbury, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • Prostate specific antigen

Drug/Treatment

  • Goserelin

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved